Literature DB >> 19505739

Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis--overlapping or separate diseases?

George J M Webster1, Stephen P Pereira, Roger W Chapman.   

Abstract

Autoimmune pancreatitis is a recently described fibroinflammatory disease which is characterised by raised serum levels of IgG4 (in >70% of cases), and an IgG4-positive lymphoplasmacytic tissue infiltrate. A favourable and rapid clinical response to oral steroid therapy is often seen. Biliary involvement is common, and the term IgG4-associated cholangitis has recently been coined. The cholangiographic appearances of IgG4-associated cholangitis and primary sclerosing cholangitis can be difficult to differentiate. Moreover, raised levels of serum IgG4 have been recently found in 9% of patients with primary sclerosing cholangitis (a much higher frequency than for other gastrointestinal diseases), and those with raised levels appear to progress more rapidly to liver failure. Here we review the similarities and differences between the biliary disease in autoimmune pancreatitis and primary sclerosing cholangitis, and address the issue of disease overlap. Improvements in understanding the relationship between these conditions might lead to an enhanced understanding of the aetiopathogenesis, and improved treatment of both conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505739     DOI: 10.1016/j.jhep.2009.04.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

Review 1.  Management of primary sclerosing cholangitis: conventions and controversies.

Authors:  Natasha Chandok; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

2.  IgG4-associated cholangitis with cholangiocarcinoma.

Authors:  Beate K Straub; Irene Esposito; Daniel Gotthardt; Boris Radeleff; Dalibor Antolovic; Christa Flechtenmacher; Peter Schirmacher
Journal:  Virchows Arch       Date:  2011-04-12       Impact factor: 4.064

3.  Immunoglobulin g4-associated autoimmune cholangiopathy.

Authors:  Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

4.  Autoimmune pancreatitis and primary sclerosing cholangitis in a 16-year-old boy with inflammatory bowel disease.

Authors:  Alexander Huelsen; Wayne Bailey; Martin Whitehead; Teresa Chalmers-Watson
Journal:  Clin J Gastroenterol       Date:  2012-03-07

Review 5.  Controversies in the management of primary sclerosing cholangitis.

Authors:  Jeremy S Nayagam; Stephen P Pereira; John Devlin; Phillip M Harrison; Deepak Joshi
Journal:  World J Hepatol       Date:  2016-02-18

6.  Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma.

Authors:  Evangelos Kalaitzakis; Michael Levy; Terumi Kamisawa; Gavin J Johnson; Todd H Baron; Mark D Topazian; Naoki Takahashi; Atsushi Kanno; Kazuichi Okazaki; Naoto Egawa; Kazushige Uchida; Kashif Sheikh; Zahir Amin; Tooru Shimosegawa; Neomal S Sandanayake; Nicholas I Church; Michael H Chapman; Stephen P Pereira; Suresh Chari; George J M Webster
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-06       Impact factor: 11.382

7.  Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis.

Authors:  Takehiro Kato; Atsumasa Komori; Sung-Kwan Bae; Kiyoshi Migita; Masahiro Ito; Yasuhide Motoyoshi; Seigo Abiru; Hiromi Ishibashi
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

Review 8.  IgG4-related hepatobiliary disease: an overview.

Authors:  Emma L Culver; Roger W Chapman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

Review 9.  A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Authors:  Elizabeth C Goode; Simon M Rushbrook
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

10.  Treatment of autoimmune liver disease: current and future therapeutic options.

Authors:  Palak J Trivedi; Gideon M Hirschfield
Journal:  Ther Adv Chronic Dis       Date:  2013-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.